SCHEMBL14342956

SCHEMBL14342956

Nc1ccc2c(c1)nc(-c1ccccc1)c1cc(Oc3ccc4c(c3)Cc3cc(Oc5ccc6c(c5)c(-c5ccccc5)nc5cc(N)ccc56)ccc3-4)ccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.49
▸ ALDH1A1 P00352 4/20 0.49
▸ MEN1 O00255 4/20 0.49
▸ MAPT P10636 3/20 0.49
▸ LMNA P02545 3/20 0.49
▸ GPR55 Q9Y2T6 1/20 0.49
▸ ATM Q13315 2/20 0.44
▸ TLR9 Q9NR96 1/20 0.44
▸ ACHE P22303 8/20 0.44
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ HPGD P15428 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ EGLN2 Q96KS0 1/20 0.37
▸ EGLN1 Q9GZT9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14342934 0.95 KMT2A (0.52) KMT2AALDH1A1MEN1MAPTLMNA
SCHEMBL15093295 0.83 KMT2A (0.38) KMT2AALDH1A1MEN1MAPTLMNA
SCHEMBL15093307 0.79 KMT2A (0.40) KMT2AALDH1A1MEN1MAPTLMNA
SCHEMBL29460850 0.78 KMT2A (0.64) KMT2AALDH1A1MEN1MAPTLMNA
SCHEMBL136397 0.78 KMT2A (0.64) KMT2AALDH1A1MEN1MAPTLMNA
Hydrochloric Acid SCHEMBL8505910 0.77 KMT2A (0.62) KMT2AALDH1A1MEN1MAPTLMNA
Hydrochloric Acid SCHEMBL7049504 0.77 KMT2A (0.62) KMT2AALDH1A1MEN1MAPTLMNA
Iodide SCHEMBL18040116 0.77 KMT2A (0.62) KMT2AALDH1A1MEN1MAPTLMNA
Hydrochloric Acid SCHEMBL8512975 0.77 KMT2A (0.62) KMT2AALDH1A1MEN1MAPTLMNA
Iodide SCHEMBL29597673 0.77 KMT2A (0.62) KMT2AALDH1A1MEN1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2692775-B1 POLYIMIDE, POLYIMIDE-BASED POLYMER ELECTROLYTE MEMBRANE, MEMBRANE- ELECTRODE ASSEMBLY, AND POLYMER ELECTROLYTE FUEL CELL NITTO DENKO CORP (JP) 2015-04-08 — — EP disclosed
US-20140235896-A1 NOVEL DIAMINE COMPOUND NITTO DENKO CORPORATION (JP) 2014-08-21 — — US disclosed
US-8748664-B2 Diamine compound and production method thereof NITTO DENKO CORPORATION (JP) 2014-06-10 — — US disclosed
EP-2692775-A1 POLYIMIDE, POLYIMIDE POLYMER ELECTROLYTE MEMBRANE, MEMBRANE ELECTRODE ASSEMBLY, AND SOLID POLYMER FUEL CELL Nitto Denko Corporation (JP) 2014-02-05 — — EP disclosed
US-20130171541-A1 POLYIMIDE, POLYIMIDE-BASED POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTRODE ASSEMBLY, AND POLYMER ELECTROLYTE FUEL CELL NITTO DENKO CORPORATION (JP) 2013-07-04 — — US disclosed
US-20130006017-A1 NOVEL DIAMINE COMPOUND AND PRODUCTION METHOD THEREOF NITTO DENKO CORPORATION (JP) 2013-01-03 — — US disclosed
EP-2540699-A1 NOVEL DIAMINE COMPOUND AND PRODUCTION METHOD THEREOF Nitto Denko Corporation (JP) 2013-01-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130006017-A1 NOVEL DIAMINE COMPOUND AND PRODUCTION METHOD THEREOF AOC1, SAT1, ODC1 KMT2A 485/4885ALDH1A1 100/4885MEN1 1742/4885
US-20140235896-A1 NOVEL DIAMINE COMPOUND AOC1, SAT1, ARG1 KMT2A 272/4885ALDH1A1 55/4885MEN1 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback